The ONL difference

ONL Therapeutics is pioneering an entirely new approach to preserving sight and halting vision loss associated with a range of retinal disease. The company is advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway.


ONL1204, the company’s lead therapeutic candidate is a first-in-class small peptide Fas inhibitor designed to protect the retina from cell death via both direct and inflammatory signaling in a range of retinal diseases.

Contact Us

Start typing and press Enter to search